Manufacturing Lilly inflates US facility investment spending by $4.5bn PharmaphorumHaving already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.Read full story pharminent May 6, 2026 (Last updated: May 7, 2026) Pharmaphorum Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante. Read full story Post navigation Previous: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand OversightNext: Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
